Slide background
Slide background




Safe design and operation of on site generation of oxygen 93% for medical use

ID 1668 | | Visite: 7658 | Documenti Chemicals EntiPermalink: https://www.certifico.com/id/1668



Safe design and operation of on site generation of oxygen 93% for medical use

Oxygen for medicinal use is a prime requirement for all healthcare facilities for both the treatment of patients with respiratory disease and for providing additional oxygen to patients being treated within the facility.

For those hospitals and clinics, where the demand is higher, oxygen is normally distributed throughout the facility using a medical gas pipeline system.

The design requirements for the supply source used to supply medical oxygen to the pipeline system are detailed in the standard, EN ISO 7396-1 Medical gas pipeline systems; Pipeline systems for compressed medical gases and vacuum.

Two different products are included in the standard:

- Medicinal oxygen supplied from liquid oxygen vessels and/or gaseous oxygen cylinders; and
- Oxygen 93 manufactured on-site within the healthcare facility, using an oxygen concentrator unit.

Medicinal oxygen supplied either in cylinders or as a cryogenic liquid, is required to be manufactured by an approved supplier with a manufacturers licence (to demonstrate compliance with guidelines detailed in the European Commission’s Guide to Good Manufacturing Practice (GMP))

Within the European Union, the supplier of medical oxygen is required to hold a marketing authorisation in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, detailing the clinical indications and contraindications and specific warnings for the safe use of the product.

The specification of this medical oxygen is detailed in the European Pharmacopoeia monograph for medical oxygen, which specifies a minimum purity of 99.5% oxygen.

The quality, safety and efficacy of the medical oxygen are ensured by the medical gas supplier through a quality management system under the responsibility of a qualified person.

Oxygen 93 can be manufactured on-site within the healthcare facility, under the responsibility of the healthcare facility pharmacist, using an oxygen 93 supply system and meeting the appropriate and specific quality and safety criteria for medicinal products prepared in Pharmacies (see Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide PE010-4 Guideline to good practices for the preparation of medicinal products in healthcare establishment).

Oxygen 93 is not being ‘put on the market’, so it currently falls outside the regulation for the manufacture and supply of medicinal product Directive 2001/83/EC.

Oxygen 93 concentrator units are covered by the requirements for CE marking in accordance with the Medical Device Directive, (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices).

The specification of the oxygen manufactured using an oxygen 93 supply system is detailed in the European Pharmacopoeia monograph for oxygen 93, which specifies the oxygen content to be between 90% and 96% and gives appropriate limits and analysis methods of other possible contaminants during the production.

As the oxygen 93 is produced by adsorbing the nitrogen from ambient air, the major contaminant in oxygen 93 is argon, which can be present up to 5%.

When the oxygen 93% monograph was introduced it was stated that the benefits of PSA oxygen (oxygen 93 per cent) are to allow production and supply of oxygen at sites where access for cylinder and liquid oxygen supply is difficult or impossible. PSA concentrators are in use in a number of fields particularly by the military (field hospitals).

The quality of the gas is very much dependent upon the performance of the equipment that produces it.

At the time of preparation of this publication, oxygen 93 is not licensed under a marketing authorisation, thus it is not evaluated by regulatory authorities and thus it cannot be considered as “equivalent medicine” for the oxygen.

EIGA 2015

Descrizione Livello Dimensione Downloads
Allegato riservato Safe Design and Operation On Site Generation Oxygen 93 for Medical Use.pdf
EIGA 2015
291 kB 16

Tags: Chemicals EIGA

Articoli correlati

Ultimi archiviati Chemicals

REACH Authorisation List
Giu 09, 2025 69

REACH Authorisation Decisions List / Last update: 23.05.2025

REACH Authorisation Decisions List / Last update: 23.05.2025 ID 24091 | Last update: 09.06.2025 REACH Authorisation Decisions List of authorisation decisions adopted on the basis of Article 64 of Regulation (EC) No 1907/2006 (REACH). The list also includes reference to related documentation… Leggi tutto
In situ generated active substances and their products
Giu 07, 2025 152

In situ generated active substances and their products

In situ generated active substances and their products / ECHA Aprile 2025 ID 24087 | 07.06.2025 / Version 2 April 2025 Information requirements and risk assessment for approval and authorisation Recommendations of the BPC Working Groups.________ Il presente documento ha lo scopo di assistere gli… Leggi tutto
Giu 06, 2025 303

Rettifica regolamento (UE) 2023/2055 - 06.06.2025

Rettifica regolamento (UE) 2023/2055 - 06.06.2025 ID 24080 | 06.06.2025 Rettifica del regolamento (UE) 2023/2055 della Commissione, del 25 settembre 2023, recante modifica dell’allegato XVII del regolamento (CE) n. 1907/2006 del Parlamento europeo e del Consiglio concernente la registrazione, la… Leggi tutto
Documento di orientamento CE condizioni d uso simili in tutta l Unione biocidi
Giu 04, 2025 321

Documento di orientamento CE condizioni d'uso simili in tutta l’Unione biocidi

Documento di orientamento CE condizioni d'uso simili in tutta l’Unione biocidi ID 24073 | 04.06.2025 / In allegato Comunicazione della Commissione - Documento di orientamento sulla definizione di condizioni d'uso simili in tutta l'Unione conformemente all'articolo 42, paragrafo 2, del regolamento… Leggi tutto
Decisione di esecuzione  UE  2025 1074
Giu 03, 2025 350

Decisione di esecuzione (UE) 2025/1074

Decisione di esecuzione (UE) 2025/1074 / Non approvazione ossido di etilene uso nei biocidi tipo di prodotto 2 ID 24066 | 03.06.2025 Decisione di esecuzione (UE) 2025/1074 della Commissione, del 2 giugno 2025, che non approva l’ossido di etilene come principio attivo esistente ai fini del suo uso… Leggi tutto
How to prepare a Drinking Water Directive Notification of intention
Mag 30, 2025 498

How to prepare a Drinking Water Directive Notification of intention

How to prepare a Drinking Water Directive Notification of intention / ECHA June 2025 ID 24047 | 30.05.2025 / Attached The purpose of this manual is to assist in the preparation of DWD notification of intention dossiers using IUCLID. The manual provides you with detailed and practical instructions… Leggi tutto
Mag 26, 2025 721

Regolamento di esecuzione (UE) 2025/973

Regolamento di esecuzione (UE) 2025/973 ID 24020 | 26.05.2025 Regolamento di esecuzione (UE) 2025/973 della Commissione, del 23 maggio 2025, recante modifica e rettifica del regolamento di esecuzione (UE) 2021/1165 che autorizza l’utilizzo di taluni prodotti e sostanze nella produzione biologica e… Leggi tutto

Più letti Chemicals

Notifica HACCP
Apr 05, 2022 101453

Notifica ai fini registrazione Regolamento CE n. 852/2004

Notifica ai fini della registrazione (Reg. CE n. 852/2004) - Ex notifica sanitaria alimentare ID 7901 | 06.03.2019 / Modello notifica allegato [panel]Regolamento (CE) 852/2004...Articolo 6 Controlli ufficiali, registrazione e riconoscimento 1. Gli operatori del settore alimentare collaborano con le… Leggi tutto